Effect of the phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide production in immunostimulated J774.1 macrophages

European Journal of Pharmacology

Volumn 339, Issue 2-3, 1997, Pages 215-221

  Németh, Zoltán H ^a   Szabó, Csaba ^a,b   Haskó, György ^a   Salzman, Andrew L ^b   Vizi, E Sylvester ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

cAMP; cGMP; Interleukin 10; Lipopolysaccharide; Macrophage; Monocyte; Nitric oxide (NO); Phosphodiesterase III inhibitor; TNF (tumor necrosis factor )

Indexed keywords

AMRINONE; CYCLIC AMP; CYCLIC GMP; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; IMMUNOMODULATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMRINONE; ANIMALS; CELL CULTURE TECHNIQUES; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MONOCYTES; NITRIC OXIDE; NITRITES; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344653633     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01392-7     Document Type: Article

References (41)

1. Allen-Webb E.M., Ross M.P., Pappas J.B., McGough E.C., Banner W. Jr. Age-related amrinone pharmacokinetics in a pediatric population. Crit. Care Med. 22:1994;1016-1024.
2. Beutler B. TNF, immunity and inflammatory disease: Lessons of the past decade. J. Invest. Med. 43:1995;227-235.
3. Dinarello C.A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and the treatment of the septic shock syndrome. J. Infect. Dis. 163:1991;1177-1184.
4. Earl C.Q., Linden J., Weglicki W.B. Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone. Life Sci. 39:1986;1901-1908.
5. Elenkov I.J., Haskó G., Kovács K.J., Vizi E.S. Modulation of lipopolysaccharide-induced tumor necrosis factor-α production by selective α- and β-adrenergic drugs in mice. J. Neuroimmunol. 61:1995;123-131.
6. Endres S., Sinha B., Fülle H.J. Amrinone suppresses the synthesis of tumor necrosis factor-α in human mononuclear cells. Shock. 5:1994;377-380.
7. Ertel W., Keel M., Steckholzer U., Ungethüm U., Trentz O. Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia. Arch. Surg. 131:1996;51-56.
8. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:1991;3815-3822.
9. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin 10 reduces the release of tumor necrosis factor-α and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:1993;547-550.
10. Giroir B.P., Beutler B. Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ. Shock. 36:1992;200-207.
11. Harbrecht B.G., Wang S.C., Simmons R.L., Billiar T.R. Cyclic GMP and guanylate cyclase mediate lipopolysaccharide-induced Kupffer cell tumor necrosis factor-α synthesis. J. Leukocyte Biol. 57:1995;297-302.
12. 2 adrenoceptors on plasma levels of tumor necrosis factor-α, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J. Endocrinol. 144:1995;457-462.
13. Haskó G., Szabó C., Merkel K., Bencsics A., Zingarelli B., Kvetan V., Vizi E.S. Modulation of lipopolysaccharide-induced tumor necrosis factor-α and nitric oxide production by dopamine receptor agonist and antagonists in mice. Immunol. Lett. 49:1996;143-147.
14. Haskó G., Szabó C., Németh Z.H., Kvetan V., Pastores S.M., Vizi E.S. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:1996;4634-4640.
15. Jilg S., Barsig J., Leist M., Küsters S., Volk H.-D., Wendel A. Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxic shock. J. Pharmacol. Exp. Ther. 278:1996;421-431.
16. Kambayashi T., Jacob C.O., Zhou D., Mazurek N., Fong M., Strassmann G. Cyclic nucleotide phosphodiesterase type IV participates in regulation of IL-10 and the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155:1995;4909-4916.
17. Katakami Y., Nakao Y., Koizumi T., Katakami N., Ogawa R., Fujita T. Regulation of tumor necrosis factor production by mouse peritoneal macrophages: The role of cellular cyclic AMP. Immunology. 64:1988;719-724.
18. Lo C.-J., Garcia I., Cryer H.G., Maier R.V. Calcium and calmodulin regulate lipopolysaccharide-induced alveolar macrophage production of tumor necrosis factor and procoagulant activity. Arch. Surg. 131:1996;44-50.
19. Mancini D., LeJemtel T., Sonnenblick E. Intravenous use of amrinone for the treatment of the failing heart. Am. J. Cardiol. 56:1985;8B-15B.
20. Marchant A., Bruyns C., Vandenabeele P., Ducarme M., Gerard C., Delvaux A., de Groote D., Abramowicz C., Velu T., Goldman M. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24:1994;1167-1171.
21. Mossmann T.R. Properties and functions of interleukin-10. Adv. Immunol. 56:1994;1-26.
22. Müller J.M., Ziegler-Heitbrock H.W.L., Baeuerle P.A. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology. 187:1993;211-256.
23. Murray K.J., England P.J., Hallam T.J., Maguire J., Moores K., Reeves M.L., Simpson A.W.M., Rink T.J. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Br. J. Pharmacol. 99:1990;612-616.
24. Németh Z.H., Haskó G., Szabó C., Vizi E.S. Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice. Shock. 7:1997;371-375.
25. Pastores S.M., Haskó G., Vizi E.S., Kvetan V. Cytokine production and its manipulation by vasoactive drugs. New Horiz. 4:1996;252-264.
26. 2 and cyclic nucleotides. J. Immunol. 141:1988;2388-2393.
27. Sato Y., Matsumori A., Sasayama S. Inotropic agent vesnarninone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J. Mol. Cell. Cardiol. 27:1995;2265-2273.
28. Sinha B., Semmler J., Eisenhut T., Eigler A., Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25:1995;147-153.
29. Souness J.E., Griffin M., Maslen C., Ebsworth K., Scott L.C., Pollock K., Palfreyman M.N., Karlsson J.A. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF-α generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 118:1996;649-658.
30. Standiford T.J., Strieter R.M., Lukacs N.W., Kunkel S.L. Neutralization of IL-10 increases lethality in endotoxemia: Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155:1995;2222-2229.
31. 2. J. Exp. Med. 180:1994;2365-2370.
32. Szabó C. Alteration in the production of nitric oxide in various forms of circulatory shock. New Horiz. 3:1995;2-32.
33. Szabó C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischaemia-reperfusion injury. Shock. 6:1996;79-88.
34. Szabó C. Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res. Bull. 41:1996;131-141.
35. Szabó C., Wu C.C., Gross S.S., Thiemermann C., Perretti M., Vane J.R. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur. J. Pharmacol. 250:1993;157-160.
36. Szabó C., Wu C.C., Mitchell J.A., Gross S.S., Thiemermann C., Vane J.R. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ. Res. 73:1993;991-999.
37. Szabó C., Thiemermann C., Vane J.R. Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem. Biophys. Res. Commun. 196:1993;825-830.
38. Thiemermann C., Wu C.C., Szabó C., Peretti M., Vane J.R. Tumor necrosis factor is an endogenous mediator of the induction of nitric oxide synthase in endotoxin shock in the rat. Br. J. Pharmacol. 110:1993;177-182.
39. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax. 46:1991;512-523.
40. Verghese M.W., McConnell R.T., Strickland A.B., Gooding R.C., Stimpson S.A., Yarnall D.P., Taylo J.D., Furdon P.J. Differential regulation of human monocyte-derived TNF-α and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272:1995;1313-1320.
41. Zingarelli B., Salzman A.L., Szabó C. Protective effects of nicotinamide against nitric oxide-mediated vascular failure in endotoxic shock: Potential involvement of polyADP ribosyl synthetase. Shock. 5:1996;258-264.